Overview

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.